Dec 18 |
Checkpoint stock plunges 50% on FDA rejection of skin cancer drug
|
Dec 18 |
UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy
|
Dec 18 |
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
|
Dec 11 |
3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
|
Dec 5 |
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
|
Nov 17 |
Checkpoint Therapeutics files to sell 6.33M shares of common stock for holders
|
Nov 14 |
Checkpoint Therapeutics GAAP EPS of -$0.29 beats by $0.46
|
Nov 13 |
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
|